Clinical Trials Directory

Trials / Completed

CompletedNCT03950440

Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement

Assessing the Incidence of Postoperative Delirium Following Aortic Valve Surgery

Status
Completed
Phase
Study type
Observational
Enrollment
250 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
70 Years
Healthy volunteers
Not accepted

Summary

Our primary aim in this observational study is to identify the incidence of POD in the first five postoperative days by using the 3-minute Diagnostic confusion assessment method (3D-CAM), the derived version for intensive care unit (CAM-ICU) or nurse reports in patients undergoing different techniques of aortic valve replacement. Patients are followed 5 days postoperative with the 3D-CAM or until resolution of POD. Six months postoperatively, a follow-up by phone is planned for activity of daily living (ADL).

Detailed description

A significant and often underrecognized complication after surgery is postoperative delirium (POD) causing increased morbidity and mortality. This is especially true for the older cardiac surgical patient, in whom the incidence of POD is up to 70%. Surgical invasiveness and herewith related inflammation, a cholinergic load of medications, postoperative pain or use of opioids are examples of precipitating factors that can be altered to reduce the incidence of POD. Transaortic valve replacement (TAVR) is a revolutionary technique that has led to a dramatic decrease in surgical invasiveness and improved outcomes in high-risk surgical patients. However, only a few studies evaluated neurocognitive outcome after surgical aortic valve replacement (SAVR) compared to TAVR, suggesting a reduced incidence of POD with TAVR compared to SAVR. In contrast, other studies found almost no difference in POD in the aforementioned patient groups. Hence, it remains still unclear which technique best to use in patients at high risk for POD.

Conditions

Timeline

Start date
2018-09-23
Primary completion
2020-01-20
Completion
2020-07-09
First posted
2019-05-15
Last updated
2023-02-16
Results posted
2023-02-16

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03950440. Inclusion in this directory is not an endorsement.